Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
OSIM
Cancer Type
Lung,
Non-Small Cell
Intent
Adjuvant
Regimen Category
Evidence-Informed
Funding Program
Exceptional Access Program
osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations, based on criteria
Drugs in Regimen
Regimen Monograph
Nov 2025
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: August 12, 2026
